PTPRC and neoplasm: MEDI9197 induced an increase in total effector T cells (ratio of Teff (CD45+/TCRβ+/CD44+/CD62L−) to Tnaive/CM (CD45+/TCRβ+/CD44+/−/CD62L+) and effector CD8+ T cells (ratio of CD45+/TCRβ+/CD8α+/CD44+/CD62L− to Tnaive/CM) in the tumor 6–8 days after dosing (Fig. 5e, Additional file 1: Fig. 6e).